Biogen bites back at critics of Aduhelm after drug’s slow startBiogen has reported $2m in sales for newly-launched Alzheimer’s therapy Aduhelm that came in below its expectations, prompting Share XBiogen bites back at critics of Aduhelm after drug’s slow starthttps://pharmaphorum.com/news/biogen-bites-back-at-critics-of-aduhelm-after-drugs-slow-start/
Study finds jabs cut severe variant COVID disease after one shotA real-world study carried out in Canada has found that COVID-19 vaccines from AstraZeneca, Pfizer/BioNTech and Moderna reduce Share XStudy finds jabs cut severe variant COVID disease after one shothttps://pharmaphorum.com/news/study-finds-jabs-cut-severe-variant-covid-disease-after-one-shot/
Happify launches Ensemble DTx for depression, anxiety in USHappify Health has launched a prescription digital therapeutic (DTx) – called Ensemble – that can assist the treatment Share XHappify launches Ensemble DTx for depression, anxiety in UShttps://pharmaphorum.com/news/happify-launches-ensemble-dtx-for-depression-anxiety-in-us/
Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
Ogilvy Health promotes Rebecca Carter to Head of Social MediaOgilvy Health UK has promoted Rebecca Carter to the newly created role of Head of Social Media. Carter Share XOgilvy Health promotes Rebecca Carter to Head of Social Mediahttps://pharmaphorum.com/sales-marketing/ogilvy-health-promotes-rebecca-carter-to-head-of-social-media/
NHS sets aside £340m for new Innovative Medicines FundNHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of Share XNHS sets aside £340m for new Innovative Medicines Fundhttps://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/
Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readoutPhase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of Share XRoche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readouthttps://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/
NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
Digital mental health specialist Woebot raises $90mInvestments in digital health firms are running high at the moment, and a $90 million round for four-year-old Share XDigital mental health specialist Woebot raises $90mhttps://pharmaphorum.com/news/digital-mental-health-specialist-woebot-raises-90m/
Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
Novartis eyes New Year verdict from FDA on delayed LeqvioNovartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by Share XNovartis eyes New Year verdict from FDA on delayed Leqviohttps://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/
Crowdsourced science refines AI prediction of clinical trial outcomesThink of the R&D dollars that could be saved if artificial intelligence (AI) modelling could tell you at Share XCrowdsourced science refines AI prediction of clinical trial outcomeshttps://pharmaphorum.com/news/crowdsourced-science-refines-ai-prediction-of-clinical-trial-outcomes/
Is J&J nearing the end of its opioid liability hangover?Johnson & Johnson and the ‘big three’ US pharma wholesalers are on the brink of a $26 billion Share XIs J&J nearing the end of its opioid liability hangover?https://pharmaphorum.com/news/is-jj-nearing-the-end-of-its-opioid-liability-hangover/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
Hard times at Ardelyx as FDA rejects kidney disease drug tenapanorThe FDA has taken a longer than usual look at Ardelyx’s regulatory submission for tenapanor, a drug for Share XHard times at Ardelyx as FDA rejects kidney disease drug tenapanorhttps://pharmaphorum.com/news/hard-times-at-ardelyx-as-fda-rejects-kidney-disease-drug-tenapanor/
FDA gives speedy review to Bayer’s Parkinson’s stem cell therapyBayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based Share XFDA gives speedy review to Bayer’s Parkinson’s stem cell therapyhttps://pharmaphorum.com/news/fda-gives-speedy-review-to-bayers-parkinsons-stem-cell-therapy/
Arcus’ CMO Grossman jumps ship to join Gilead’s cancer pushGilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief Share XArcus’ CMO Grossman jumps ship to join Gilead’s cancer pushhttps://pharmaphorum.com/news/arcus-cmo-grossman-jumps-ship-to-join-gileads-cancer-push/
Computer model simulates COVID infection, and treatmentResearchers in Canada have built a computer model that replicates how the human immune system interacts with the Share XComputer model simulates COVID infection, and treatmenthttps://pharmaphorum.com/news/computer-model-simulates-covid-infection-and-treatment/
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor Share XThe key to psoriasis innovation? Dispelling the shadow of the JAK inhibitorhttps://pharmaphorum.com/partner-content/the-key-to-psoriasis-innovation-dispelling-the-shadow-of-the-jak-inhibitor/
Complex Medicines: A multi-billion-pound addition to the UK life sciences industry Share XComplex Medicines: A multi-billion-pound addition to the UK life sciences industryhttps://pharmaphorum.com/partner-content/complex-medicines-a-multi-billion-pound-addition-to-the-uk-life-sciences-industry/
PRIYSM ID boosts customer service offer with new customer experience team Share XPRIYSM ID boosts customer service offer with new customer experience teamhttps://pharmaphorum.com/partner-content/priysm-id-boosts-customer-service-offer-with-new-customer-experience-team/
KOL Mindset Mapping Share XKOL Mindset Mappinghttps://pharmaphorum.com/partner-content/kol-mindset-mapping/
Prescient Healthcare Group to Partner with Bridgepoint Development Capital Share XPrescient Healthcare Group to Partner with Bridgepoint Development Capitalhttps://pharmaphorum.com/partner-content/prescient-healthcare-group-to-partner-with-bridgepoint-development-capital/
Prescient Announces Recent Appointments to its Senior Team Share XPrescient Announces Recent Appointments to its Senior Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/
